Literature DB >> 9444989

Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse.

J F Moffat1, L Zerboni, P R Kinchington, C Grose, H Kaneshima, A M Arvin.   

Abstract

The SCID-hu mouse implanted with human fetal tissue is a novel model for investigating human viral pathogenesis. Infection of human skin implants was used to investigate the basis for the clinical attenuation of the varicella-zoster virus (VZV) strain, V-Oka, from which the newly licensed vaccine is made. The pathogenicity of V-Oka was compared with that of its parent, P-Oka, another low-passage clinical isolate, strain Schenke (VZV-S), and VZV-Ellen, a standard laboratory strain. The role of glycoprotein C (gC) in infectivity for human skin was assessed by using gC-negative mutants of V-Oka and VZV-Ellen. Whereas all of these VZV strains replicated well in tissue culture, only low-passage clinical isolates were fully virulent in skin, as shown by infectious virus yields and analysis of implant tissues for VZV DNA and viral protein synthesis. The infectivity of V-Oka in skin was impaired compared to that of P-Oka, providing the first evidence of a virologic basis for the clinical attenuation of V-Oka. The infectivity of V-Oka was further diminished in the absence of gC expression. All strains except gC-Ellen retained some capacity to replicate in human skin, but cell-free virus was recovered only from implants infected with P-Oka or VZV-S. Although VZV is closely related to herpes simplex virus type 1 (HSV-1) genetically, experiments in the SCID-hu model revealed differences in tropism for human cells that correlated with differences in VZV and HSV-1 disease. VZV caused extensive infection of epidermal and dermal skin cells, while HSV-1 produced small, superficial lesions restricted to the epidermis. As in VZV, gC expression was a determinant for viral replication in skin. VZV infects human CD4+ and CD8+ T cells in thymus/liver implants, but HSV-1 was detected only in epithelial cells, with no evidence of lymphotropism. These SCID-hu mouse experiments show that the clinical attenuation of the varicella vaccine can be attributed to decreased replication of V-Oka in skin and that tissue culture passage alone reduces the ability of VZV to infect human skin in vivo. Furthermore, gC, which is dispensable for replication in tissue culture, plays a critical role in the virulence of the human alphaherpesviruses VZV and HSV-1 for human skin.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9444989      PMCID: PMC124567          DOI: 10.1128/JVI.72.2.965-974.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Infection of polarized MDCK cells with herpes simplex virus 1: two asymmetrically distributed cell receptors interact with different viral proteins.

Authors:  A E Sears; B S McGwire; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

2.  Glycoprotein C of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and in infectivity.

Authors:  B C Herold; D WuDunn; N Soltys; P G Spear
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

3.  A possible role for glycoprotein gpV in the pathogenesis of varicella-zoster virus.

Authors:  P R Kinchington; P Ling; M Pensiero; A Gershon; J Hay; W T Ruyechan
Journal:  Adv Exp Med Biol       Date:  1990       Impact factor: 2.622

4.  The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content.

Authors:  R E Bergen; P S Diaz; A M Arvin
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

5.  Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization.

Authors:  C M Koropchak; S M Solem; P S Diaz; A M Arvin
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

6.  Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia.

Authors:  R Mahalingam; M Wellish; W Wolf; A N Dueland; R Cohrs; A Vafai; D Gilden
Journal:  N Engl J Med       Date:  1990-09-06       Impact factor: 91.245

7.  Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge.

Authors:  S A Plotkin; S E Starr; H M Friedman; E Gönczöl; R E Weibel
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

8.  Human immunodeficiency virus infection of human lymph nodes in the SCID-hu mouse.

Authors:  H Kaneshima; C C Shih; R Namikawa; L Rabin; H Outzen; S G Machado; J M McCune
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

9.  A detailed analysis of transcripts mapping to varicella zoster virus gene 14 (glycoprotein V).

Authors:  P Ling; P R Kinchington; W T Ruyechan; J Hay
Journal:  Virology       Date:  1991-10       Impact factor: 3.616

10.  Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella.

Authors:  C M Koropchak; G Graham; J Palmer; M Winsberg; S F Ting; M Wallace; C G Prober; A M Arvin
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

View more
  99 in total

1.  A herpes simplex virus 1 recombinant lacking the glycoprotein G coding sequences is defective in entry through apical surfaces of polarized epithelial cells in culture and in vivo.

Authors:  L C Tran; J M Kissner; L E Westerman; A E Sears
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

2.  Construction of varicella-zoster virus recombinants from parent Oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model.

Authors:  Takahiro Niizuma; Leigh Zerboni; Marvin H Sommer; Hideki Ito; Stewart Hinchliffe; Ann M Arvin
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

3.  Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus.

Authors:  Yasuyuki Gomi; Hiroki Sunamachi; Yasuko Mori; Kazuhiro Nagaike; Michiaki Takahashi; Koichi Yamanishi
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

4.  Marek's disease virus expresses multiple UL44 (gC) variants through mRNA splicing that are all required for efficient horizontal transmission.

Authors:  Keith W Jarosinski; Nikolaus Osterrieder
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

5.  Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection.

Authors:  Barbara Berarducci; Minako Ikoma; Shaye Stamatis; Marvin Sommer; Charles Grose; Ann M Arvin
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

6.  Delayed biosynthesis of varicella-zoster virus glycoprotein C: upregulation by hexamethylene bisacetamide and retinoic acid treatment of infected cells.

Authors:  Johnathan Storlie; Wallen Jackson; Jennifer Hutchinson; Charles Grose
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 7.  Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model.

Authors:  Chia-Chi Ku; Jaya Besser; Allison Abendroth; Charles Grose; Ann M Arvin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

8.  Varicella-zoster vaccine virus: evolution in action.

Authors:  Jeffrey I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

9.  The insulin degrading enzyme binding domain of varicella-zoster virus (VZV) glycoprotein E is important for cell-to-cell spread and VZV infectivity, while a glycoprotein I binding domain is essential for infection.

Authors:  Mir A Ali; Qingxue Li; Elizabeth R Fischer; Jeffrey I Cohen
Journal:  Virology       Date:  2009-02-23       Impact factor: 3.616

10.  Replication of varicella-zoster virus in human skin organ culture.

Authors:  Shannon L Taylor; Jennifer F Moffat
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.